Genetic studies in treatment-resistant schizophrenia

Advances in Biological Psychiatry

Volumn 26, Issue , 2010, Pages 52-62

  De Luca, Vincenzo ^a   Souza, Renan P ^a   Panariello, Fabio ^a   Meltzer, Herbert Y ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867492914     PISSN: 03787354     EISSN: 16622774     Source Type: Book Series    
DOI: 10.1159/000319808     Document Type: Article

References (56)

1. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C: Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980;6:70-87.
2. Klein DF, Davis JM: Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, Williams & Wilkins, 1969.
3. Weiss EL, Longhurst JG, Bowers MB Jr, Mazure CM: Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine. J Clin Psychopharmacol 1999;19:378-380.
4. Kane JM, Honigfeld G, Singer J, Meltzer H: Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 1988;24:62-67.
5. Inada T, Nakamura A, Iijima Y: Relationship between catechol-O- methyltransferase polymorphism and treatment-resistant schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003;120B:35- 39.
6. Sharma T, Kerwin R: Biological determinants of difficult to treat patients with schizophrenia. Br J Psychiatry 1996;169(supp 31):5-9.
7. Crosthwaite CG, Reveley MA: Structural imaging and treatment response in schizophrenia; in Reveley MA, William-Deakin JF (eds): The Psychopharmacology of Schizophrenia. London, Arnold, 2000, pp 89-108.
8. Christison GW, Kirch DG, Wyatt RJ: When symptoms persist: Choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991; 17:217-245.
9. Bowers MB, Swigar ME, Jatlow PI, Goicoechea N: Plasma catecholamine metabolites and early response to haloperidol. J Clin Psychiatry 1984;45:248-251.
10. Buchsbaum MS, Potkin SG, Marshall JF, Lottenberg S, Teng C, Heh CW, Tafalla R, Reynolds C, Abel L, Plon L: Effects of Clozapine and thiothixene on glucose metabolic rate in schizophrenia. Neuropsychopharmacology 1992;6:155-163.
11. Kahn RS, Davidson M, Siever L, Gabriel S, Apter S, Davis KL: Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiatry 1993;150:1337-1342.
12. Pickar D, Labaraca R, Linnoila M, Roy A, Hommer D, Everett D, Paul SM: Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 1984;225:954-957.
13. Szymanski S, Lieberman J, Pollack S, Safferman A, Munne R, Umbricht D, Kane J, Kronig M, Chakos M, Cooper T: Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: Preliminary findings. Biol Psychiatry 1995;37:52- 55.
14. Sheitman B, Lieberman J: The natural history and pathophysiology of treatment resistant schizophrenia. J Psychiatr Res 1988;32:143-150.
15. Friedman L, Lys C, Schulz SC: The relationship of structural brain imaging parameters to antipsychotic treatment response: A review. J Psychiatry Neurosci 1992;17:42-54.
16. Wilson WH: Time required for initial improvement during clozapine treatment of refractory schizophrenia. Am J Psychiatry 1996;153:951-952.
17. Bradford DW, Chakos MH, Sheitman B, Lieberman JA: Atypical antipsychotic drugs in treatmentrefractory schizophrenia. Psychiatr Ann 1998;28: 618-628.
18. Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, Cola P, Howard A, Badri F, Nothen MM, Kalow W, Kennedy JL: Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998;19:123-132.
19. Masellis M, Paterson AD, Badri F, Lieberman JA, Meltzer HY, Cavazzoni P, Kennedy JL: Genetic variation of 5-HT2A receptor and response to clozapine. Lancet 1995;346:1108.
20. Masellis M, Basile VS, Meltzer HY, Lieberman JA, Sevy S, Goldman DA, Hamblin MW, Macciardi FM, Kennedy JL: Lack of association between the T->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr Res 2001;47:49-58.
21. Yu YW, Tsai SJ, Lin CH, Hsu CP, Yang KH, Hong CJ: Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport 1999 Apr 26;10: 1231-1233.
22. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P, Kerwin R: Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995;346:281-282.
23. Arranz MJ, Collier DA, Munro J, Sham P, Kirov G, Sodhi M, Roberts G, Price J, Kerwin RW: Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett 1996;217:177-178.
24. Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham PC, Zhao J, Kirov G, Collier DA, Kerwin RW: Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998;3:61-66.
25. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JF, Sham P, Collier DA, Murray RM, Kerwin RW: Pharmacogenetic prediction of clozapine response. Lancet 2000;355: 1615-1616.
26. Sodhi MS, Arranz MJ, Curtis D, Ball DM, Sham P, Roberts GW, Price J, Collier DA, Kerwin RW: Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995;7:169-172.
27. Arranz MJ, Bolonna AA, Munro J, Curtis CJ, Collier DA, Kerwin RW: The serotonin transporter and clozapine response. Mol Psychiatry 2000;5:124-125.
28. Ji X, Takahashi N, Branko A, Ishihara R, Nagai T, Mouri A, Saito S, Maeno N, Inada T, Ozaki N: An association between serotonin receptor 3B gene (HTR3B) and treatment-resistant schizophrenia (TRS) in a Japanese population. Nagoya J Med Sci 2008;70:11-17.
29. Ji X, Takahashi N, Saito S, Ishihara R, Maeno N, Inada T, Ozaki N: Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population. Neurosci Lett 2008;435:95- 98.
30. Arranz MJ, Bolonna AA, Munro J, Curtis CJ, Collier DA, Kerwin RW: The serotonin transporter and clozapine response. Mol Psychiatry 2000;5:124-125.
31. Birkett JT, Arranz MJ, Munro J, Osbourn S, Kerwin RW, Collier DA: Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport 2000;11:2017-2020.
32. Lin CH, Tsai SJ, Yu YW, Song HL, Tu PC, Sim CB, Hsu CP, Yang KH, Hong CJ: No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport 1999;10:57-60.
33. Tsai SJ, Hong CJ, Yu YW, Lin CH, Song HL, Lai HC, Yang KH: Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophr Res 2000;44:177-181.
34. Hwang R, Shinkai T, De Luca V, Ni X, Potkin SG, Lieberman JA, Meltzer HY, Kennedy JL: Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol 2007;21:718-727.
35. Hwang R, Shinkai T, Deluca V, Macciardi F, Potkin S, Meltzer HY, Kennedy JL: Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. Eur Neuropsychopharmacol 2006;16: 248-259.
36. Hwang R, Shinkai T, De Luca V, Muller DJ, Ni X, Macciardi F, Potkin S, Lieberman JA, Meltzer HY, Kennedy JL: Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/ intolerant populations. Psychopharmacology (Berl) 2005;181:179-187.
37. Arranz MJ, Li T, Munro J, Liu X, Murray R, Collier DA, Kerwin RW: Lack of association between a polymorphism in the promoter region of the dopamine- 2 receptor gene and clozapine response. Pharmacogenetics 1998;8:481-484.
38. Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J: Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry 1994;51:912-917.
39. Shaikh S, Collier D, Kerwin RW, Pilowsky LS, Gill M, Xu WM, Thornton A: Dopamine D4 receptor subtypes and response to clozapine. Lancet 1993; 341:116.
40. Shaikh S, Collier DA, Sham P, Pilowsky L, Sharma T, Lin LK, Crocq MA, Gill M, Kerwin R: Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene(DRD4) in schizophrenic patients. Am J Med Genet 1995;60:541-545.
41. Shaikh S, Collier DA, Sham PC, Ball D, Aitchison K, Vallada H, Smith I, Gill M, Kerwin RW: Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 1996;97:714-719.
42. Arranz MJ, Dawson E, Shaikh S, Sham P, Sharma T, Aitchison K, Crocq MA, Gill M, Kerwin R, Collier DA: Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol 1995;39:417-420.
43. Aitchison KJ, Munro J, Wright P, Smith S, Makoff AJ, Sachse C, Sham PC, Murray RM, Collier DA, Kerwin RW: Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Br J Clin Pharmacol 1999;48:388-394.
44. Kohlrausch FB, Gama CS, Lobato MI, Belmontede- Abreu P, Callegari-Jacques SM, Gesteira A, Barros F, Carracedo A, Hutz MH: Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenet Genomics 2008;18:599-609.
45. Takao T, Tachikawa H, Kawanishi Y, Katano T, Sen B, Homma M, Kohda Y, Mizukami K, Asada T: Association of treatment-resistant schizophrenia with the G2677A/T and C3435T polymorphisms in the ATP-binding cassette subfamily B member 1 gene. Psychiatr Genet 2006;16:47-48.
46. Hong CJ, Yu YW, Lin CH, Tsai SJ: An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett 2003;349:206- 208.
47. Hong CJ, Yu YW, Lin CH, Song HL, Lai HC, Yang KH, Tsai SJ: Association study of apolipoprotein E epsilon4 with clinical phenotype and clozapine response in schizophrenia. Neuropsychobiology 2000;42:172-174.
48. Tsai SJ, Wang YC, Yu Younger WY, Lin CH, Yang KH, Hong CJ: Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr Res 2001;49:53-58.
49. Hong CJ, Yu YW, Lin CH, Cheng CY, Tsai SJ: Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatr Genet 2001;11:219-222.
50. Tsai SJ, Hong CJ, Yu YW, Lin CH, Liu LL: No association of tumor necrosis factor alpha gene polymorphisms with schizophrenia or response to clozapine. Schizophr Res 2003;65:27-32.
51. Mancama D, Arranz MJ, Munro J, Osborne S, Makoff A, Collier D, Kerwin R: Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neurosci Lett 2002;333:207-211.
52. Mundo E, Altamura AC, Vismara S, Zanardini R, Bignotti S, Randazzo R, Montresor C, Gennarelli M: MCP-1 gene (SCYA2) and schizophrenia: A casecontrol association study. Am J Med Genet B Neuropsychiatr Genet 2005;132B:1-4.
53. Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, Wong AH, Kennedy JL: Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) 2008;200:177-186.
54. Zai G, Muller DJ, Volavka J, Czobor P, Lieberman JA, Meltzer HY, Kennedy JL: Family and case-control association study of the tumor necrosis factoralpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology (Berl) 2006;188:171-182.
55. Muller DJ, De Luca V, Sicard T, King N, Hwang R, Volavka J, Czobor P, Sheitman BB, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA, Meltzer HY, Kennedy JL: Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. Eur Neuropsychopharmacol 2005;15:525-531.
56. Kohlrausch FB, Salatino-Oliveira A, Gama CS, Lobato MI, Belmonte-de-Abreu P, Hutz MH: G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics 2008;9:1429-1436.